Latest News by Industry
EAGAN, MN / ACCESSWIRE / September 22, 2022 / Dynatronics Corporation (NASDAQ:DYNT) ("Dynatronics" or the "Company"), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today reported financial results for its fourth quarter and fiscal year ended June 30, 2022, and provided an update on recent business highlights.
CEO Commentary
"The fourth quarter of fiscal year 2022 represented the fifth consecutive quarter of exceeding the market and our baseline net sales expectation. Net sales growth of 14% in the fourth quarter relative to continued product net sales in the same period in the prior year was a result of our customers' positive reaction to our updated business model," said John Krier, Chief Executive Officer of Dynatronics. "Strong demand, coupled with our commitment to disciplined execution, has generated confidence in our outlook, despite the significant impacts of COVID-19."
"We expect our gross margin in Q1 of fiscal year '23 to show continued expansion as we benefit from price increases for our products. Cash flow from operations in fiscal year ‘23 should begin to improve as we sell down the inventory we strategically built over the past year," concluded Krier.
Key Financial Highlights
Q4 FY '22 Financial Highlights
Note: All financials referenced in this release are in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and comparisons in this release are to the same period in the prior year unless otherwise noted.
FY '22 Financial Highlights
Guidance for FY '23
Dynatronics issued net sales guidance for FY '23 of $45 million to $48 million, assuming similar procedure volume despite the impacts of COVID-19. The midpoint of this range is a 5% improvement relative to the $44.3 million net sales in fiscal year ‘22. The Company expects the distribution of net sales across the quarters in FY '23 to align with historical trends, highest in the first quarter, lower in the second and third quarters, with a bounce back in the fourth quarter.
The Company is continuing its recent practice to not provide gross margin guidance given the persistent inflationary pressure, on-going impacts of COVID-19, and supply chain challenges. That said, Dynatronics does expect Q1 of fiscal year '23 to continue the sequential expansion towards the longer-term target of 40%.
Selling, general, and administrative expenses are anticipated to be 30% to 35% of net sales in FY '23.
Inventory is expected to remain at an elevated level to meet customer demand, and current market and supply chain conditions. Cash flow from operations in fiscal year ‘23 should begin to show improvement as the Company sells down the inventory strategically built over the past year.
The Company's financial guidance for FY '23 is subject to the risks identified in its safe harbor notification below. The Company continues to expect volatility due to the challenges related to the broader economic environment and the COVID-19 global pandemic, including higher raw material, delivery and shipment costs, supply chain disruptions, extended handling times and delays or disruption in procedure volume. Dynatronics also expects some ongoing volatility from the Company's business optimization.
Growth Priorities
The Company has delivered sales growth that outpaced market growth and baseline expectation for the fifth consecutive quarter. These are the levers to drive sales growth at the macro level: winning market share by partnering with the Company's customers, driving favorable mix shift to new product innovations, and a value creating M&A strategy.
Conference Call and Webcast Q4 and full-year FY '22 Results
The Company will hold a conference call and live audio webcast to discuss the results, consisting of prepared remarks by management, slide presentation, and a question-and-answer session with analysts, beginning at 8:00 AM ET on Thursday, September 22, 2022.
Interested persons may access the live conference call by dialing 888-506-0062 (U.S./Canada callers) or 973-528-0011 (international callers), using passcode 767607. It is recommended that participants call or log in 10 minutes ahead of the scheduled start time to ensure a proper connection. An audio replay will be available one hour after the live call until Midnight on September 29, 2022, by dialing 877-481-4010, using passcode 46504.
The live webcast and slide presentation can be accessed on the Company's Investor webpage under the Events & Presentations tab at https://irdirect.net/DYNT/corporate_document/1982. The webcast will be archived on the website for future viewing.
About Dynatronics Corporation
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Those statements include references to the Company's expectations and similar statements. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our statements regarding expected improvement in overall performance, expectations that the Company will improve long-term gross margins, operating income and cash flow from operations, expectations regarding reduction in leased space in fiscal year 2022, expectations regarding net sales, gross margin, selling general and administrative costs, and other income in fiscal year 2022, and uncertainties involving the impact of the COVID-19 global pandemic on the Company's results of operations and financial condition. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in the Company's annual, quarterly and other reports filed with the Securities and Exchange Commission.
About Non-GAAP Financial Measures
Continued product net sales as used in this press release is a non-GAAP measure as defined under the rules of the Securities and Exchange Commission. The Company defines continued product net sales as sales excluding discontinued products and sales of physical therapy and rehabilitation products through our direct sales channel. Management uses this non-GAAP measure to evaluate our operating performance and to forecast future periods. Management believes this non-GAAP measure provides investors additional information about the Company's ongoing operating performance and is not intended as a substitute for, or superior to, the financial measure prepared in accordance with GAAP. Investors are cautioned against placing undue reliance on this non-GAAP measure. $37 million annual and $9.25 million quarterly baseline continued product net sales set in April 2021 is based on annual net sales of approximately $48 million in FY '21 less estimated annual discontinued product sales of approximately $11 million.
Summary Financial Results
Following is a summary of operating results for the periods ended June 30, 2022 and 2021, the balance sheet highlights at June 30, 2022 and June 30, 2021 and cash flow for periods ended June 30, 2022 and 2021.
Summary Selected Financial Data
Statement of Operation Highlights
In thousands, except share and per share amounts
| Quarter Ended | Twelve Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Net sales | $ | 11,191 | $ | 12,238 | $ | 44,338 | $ | 47,799 | ||||||||
Cost of sales | 8,574 | 9,900 | 33,665 | 34,913 | ||||||||||||
Gross profit | 2,617 | 2,338 | 10,673 | 12,886 | ||||||||||||
| 23.4 | % | 19.1 | % | 24.1 | % | 27.0 | % | |||||||||
Selling, general, and admin. expenses | 4,102 | 4,558 | 15,430 | 16,646 | ||||||||||||
Other (expense) income, net | (78 | ) | 5,134 | 764 | 5,752 | |||||||||||
Income tax provision | - | 20 | - | 10 | ||||||||||||
Net (loss) income | $ | (1,563 | ) | $ | 2,934 | $ | (3,993 | ) | $ | 2,002 | ||||||
Deemed dividend on convertible preferred stock and accretion of discount | - | - | - | (51 | ) | |||||||||||
Convertible preferred stock dividend, in common stock | (182 | ) | (182 | ) | (733 | ) | (741 | ) | ||||||||
Net (loss) income attributable to common stockholders | $ | (1,745 | ) | $ | 2,752 | $ | (4,726 | ) | $ | 1,210 | ||||||
Net (loss) income attributable to common stockholders per common share - basic and diluted | (0.10 | ) | 0.16 | (0.26 | ) | 0.08 | ||||||||||
Weighted-average common shares outstanding - basic and diluted | 18,187,243 | 17,557,595 | 17,853,276 | 15,461,339 |
Balance Sheet Highlights
In thousands
| June 30, 2022 | June 30, 2021 | |||||||
Cash and cash equivalents and restricted cash | $ | 701 | $ | 6,254 | ||||
Trade accounts receivable, net | 5,416 | 5,643 | ||||||
Inventories, net | 12,071 | 6,526 | ||||||
Prepaid & other | 1,038 | 2,483 | ||||||
Total current assets | 19,226 | 20,906 | ||||||
Non-current assets | 16,208 | 18,234 | ||||||
Total assets | $ | 35,434 | $ | 39,140 | ||||
Accounts payable | $ | 6,169 | $ | 3,738 | ||||
Accrued payroll and benefits expense | 1,360 | 1,656 | ||||||
Accrued expenses | 862 | 1,485 | ||||||
Other current liabilities | 1,544 | 1,593 | ||||||
Total current liabilities | 9,935 | 8,472 | ||||||
Non-current liabilities | 3,800 | 5,154 | ||||||
Total liabilities | 13,735 | 13,626 | ||||||
Stockholders' equity | 21,699 | 25,514 | ||||||
Total liabilities and stockholders' equity | $ | 35,434 | $ | 39,140 |
Cash Flow Highlights
In thousands
| Quarter Ended | Twelve Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Net (loss) income | $ | (1,563 | ) | $ | 2,934 | $ | (3,993 | ) | $ | 2,002 | ||||||
Depreciation and amortization | 313 | 368 | 1,285 | 1,480 | ||||||||||||
Stock based compensation | 29 | 26 | 178 | 154 | ||||||||||||
Gain on extinguishment of debt | - | (3,518 | ) | - | (3,518 | ) | ||||||||||
(Gain) loss on sale of property and equipment | 23 | (745 | ) | 24 | (717 | ) | ||||||||||
Receivables | (290 | ) | 160 | 227 | (749 | ) | ||||||||||
Inventory | (468 | ) | 403 | (5,573 | ) | 551 | ||||||||||
Prepaid and other assets | 512 | 313 | 1,463 | (741 | ) | |||||||||||
Accounts payable, accrued expenses, and other liabilities | (181 | ) | 128 | 1,505 | 1,922 | |||||||||||
Net cash (used in) provided by operating activities | (1,625 | ) | 69 | (4,884 | ) | 384 | ||||||||||
Net cash (used in) provided by investing activities | (57 | ) | 1,620 | (319 | ) | 1,531 | ||||||||||
Net cash (used in) provided by financing activities | (90 | ) | (86 | ) | (350 | ) | 2,023 | |||||||||
Net change in cash and cash equivalents | (1,772 | ) | 1,603 | (5,553 | ) | 3,938 | ||||||||||
Cash and cash equivalents at beginning of the period | 2,473 | 4,651 | 6,254 | 2,316 | ||||||||||||
Cash and cash equivalents at end of the period | $ | 701 | $ | 6,254 | $ | 701 | $ | 6,254 |
CONTACT:
Dynatronics Corporation
Investor Relations
For additional information, please visit: www.dynatronics.com
Connect with Dynatronics on LinkedIn
SOURCE: Dynatronics Corporation
View source version on accesswire.com: https://www.accesswire.com/716997/Dynatronics-Corporation-Reports-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Business-Highlights